Screener
Core Laboratories CLB Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Core Laboratories in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The source filing: Core Laboratories’s 10-Q, filed April 30, 2026.
- Filed
- Apr 30, 2026, 6:03 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-198109
| Line item | Three Months Ended / March 31, 2026 | Three Months Ended / March 31, 2025 |
|---|---|---|
| Accrued expenses | (845) | 617 |
| Unearned revenues | (844) | 440 |
| Other liabilities | (1,932) | (1,053) |
| Net cash provided by operating activities | 3,965 | 6,660 |
| CASH FLOWS FROM INVESTING ACTIVITIES: | ||
| Capital expenditures - operations | (3,448) | (2,785) |
| Capital expenditures - rebuilding of Aberdeen facility | (1,443) | (794) |
| Proceeds from insurance recovery - Aberdeen facility | — | 3,121 |
Item 1. Financial Statements
FAQ
- What is Core Laboratories's operating cash flow?
- Core Laboratories (CLB) reported operating cash flow of $3.97M in Q1 2026.
- How has Core Laboratories's operating cash flow changed year-over-year?
- Core Laboratories's operating cash flow decreased by 40.5% year-over-year, from $6.66M to $3.97M.
- What is the long-term trend for Core Laboratories's operating cash flow?
- Over 3 years (2021 to 2025), Core Laboratories's operating cash flow has grown at a 0.4% compound annual growth rate (CAGR), from $36.58M to $37.03M.
- What does operating cash flow mean?
- Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.
Ask your AI about Core Laboratories's operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude